Paula Grondona

Paula Grondona

Auto-generated profile, based on publicly available information

Paula Grondona

Interfaculty Institute for Biochemistry, Eberhard Karls University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2020 in Blood
Verified
Journal Article
Closed access
PDF file
PBPhilip Bucher
Philip Bucher
TETabea Erdmann
Tabea Erdmann
PGPaula Grondona
Paula Grondona
WXWendan Xu
Wendan Xu
ASAnja Schmitt
Anja Schmitt
SHStephan Hailfinger
Stephan Hailfinger
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.

1 September 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PGPaula Grondona
Paula Grondona
PBPhilip Bucher
Philip Bucher
ASAnja Schmitt
Anja Schmitt
CSCaroline Schönfeld
Caroline Schönfeld
BSBarbara Irina Streibl
Barbara Irina Streibl
SHStephan Hailfinger
Stephan Hailfinger